Physician profile
Thomas Diamant
NPI 1952310872
$15,940.26
in general payments reported to CMS, 2019-2025
46 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $1,176 · 2021: $1,684 · 2022: $2,115 · 2023: $2,271 · 2024: $3,012 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,981 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,980.67 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,231.05 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals Lp | $2,101.57 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,073.00 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Regeneron Healthcare Solutions, INC. | $1,164.41 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $1,146.41 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $734.25 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $669.27 | 2021-2025 | Hyqvia, Cuvitru, Glassia |
| Genzyme Corporation | $538.53 | 2019-2025 | |
| Amgen INC. | $496.80 | 2021-2025 | Tezspire |
| Verona Pharma, INC. | $496.69 | 2025 | Ohtuvayre |
| Abbvie INC. | $440.68 | 2024-2025 | |
| Baxter Healthcare | $348.86 | 2022-2025 | Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $314.64 | 2025 | Yupelri |
| Philips North America LLC | $305.96 | 2019-2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $259.89 | 2024-2025 | Zemaira |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $250.28 | 2021-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $223.98 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $183.16 | 2020-2024 | Xarelto |
| Electromed, INC. | $169.37 | 2022-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $156.99 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $152.23 | 2019-2020 | |
| Viiv Healthcare Company | $144.82 | 2023-2024 | Dovato |
| Merck Sharp & Dohme LLC | $138.45 | 2019-2025 | Winrevair, Capvaxive |
| Sunovion Pharmaceuticals INC. | $133.74 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $117.90 | 2019-2025 | Opsumit, Uptravi |
| Paratek Pharmaceuticals, INC. | $117.23 | 2020-2025 | Nuzyra |
| Pfizer INC. | $111.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.53 | 2020-2021 | |
| Pulmonx Corporation | $77.08 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Covis Pharma Gmbh | $65.94 | 2022 | |
| Advanced Respiratory, INC | $62.60 | 2020-2021 | |
| Octapharma USA, INC. | $48.62 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.53 | 2019-2021 | |
| Inspire Medical Systems, INC. | $36.44 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $35.75 | 2025 | |
| Csl Behring | $35.13 | 2019 | |
| Harmony Biosciences LLC | $29.30 | 2022 | |
| Zoll Respicardia, INC. | $29.09 | 2024-2025 | Remede System |
| Seqirus USA INC | $24.97 | 2024 | Fluad, Flucelvax |
| Gilead Sciences, INC. | $23.08 | 2024 | |
| Sanofi Pasteur INC. | $22.07 | 2023 | |
| Endogastric Solutions, INC | $20.42 | 2019 | |
| Shionogi INC | $19.52 | 2021 | |
| Optinose US, INC. | $19.08 | 2025 | |
| Inari Medical, INC. | $18.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lilly USA, LLC | $17.34 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Diamant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.